ALZUMAb, Indian Psoriasis Drug

• The first instance of a breakthrough innovation from India with a potential to treat multiple autoimmune diseases.
• Biocon’s ALZUMAb™ (Itolizumab) is the first anti-CD6 monoclonal antibody to be commercialized, an outcome of path breaking research in India. This new line of treatment will usher in a paradigm shift in the management of psoriasis.
• What makes this drug so special is that it is an antibody that targets a surface marker on T cells! The drug targets the CD6 surface receptor, binding to it and blocking activation of T cells in inflammatory environments within the body. The surface receptor, CD6, is also important for T-cell migration to sites of inflammation and maturation to become pro-inflammatory. 
•  Reference: http://www.medicaldaily.com/alzumab-indian-psoriasis-drug-first-biologic-med-its-kind-when-will-it-hit-us-market-250987

 

Dual and pan PPAR agonists

PPAR agonists are drugs which act upon the peroxisome proliferator-activated receptor. They are used for the treatment of symptoms of the metabolic syndrome, mainly for lowering triglycerides and blood sugar.

Dual and pan PPAR agonists

• A fourth class of dual PPAR agonists, so-called glitazars, which bind to both the α and γ PPAR isoforms, are currently under active investigation for treatment of a larger subset of the symptoms of the metabolic syndrome. These include the experimental compounds aleglitazar, muraglitazar and tesaglitazar. In June 2013, saroglitazar was the first glitazar to be approved for clinical use.
• In addition, there is continuing research and development of new dual α/δ and γ/δ PPAR agonists for additional therapeutic indications, as well as "pan" agonists acting on all three isoforms.